64. Pancreatic Cancer Survival Doubled
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
64. Pancreatic Cancer Survival Doubled
-
ナレーター：
-
著者：
Summary: A biological fortress has finally been breached. We investigate the groundbreaking Phase 3 trial of Duraxonrib, a daily pill that has doubled the survival time for patients with advanced pancreatic cancer.
Full Description: For thirty years, the five-year survival rate for advanced pancreatic cancer has been trapped at a grim 3%. In this investigation, we explore how scientists finally "picked the lock" of the RAS mutation—a protein once deemed "undruggable" due to its smooth, slippery shape. We break down the data showing survival jumping from 6.7 months on standard chemotherapy to 13.2 months with this new targeted therapy. Discover how this "molecular grease" was overcome and why this oral treatment is offering more than just time—it’s offering a higher quality of life.
This podcast was AI generated and may be incomplete and contain mispronunciations or errors.